Skip to Main Content

The emergence of the Covid-19 pandemic generated renewed interest in the development of vaccines and associated technologies. Vaccines have been the big winners, but there were some gains for anti-infective therapies as well.

Before 2019, emerging companies had a difficult time flourishing in the vaccine and antimicrobial space. With few vaccine developers to partner with and biopharma exiting the antibiotic space due to commercial challenges, my colleagues and I at Back Bay Life Science Advisors found ourselves helping our clients navigate a very narrow path to funding or partnerships.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!